Google is changing its policies to allow some cannabidiol (CBD) product advertisements in certain states and U.S. territories.
A company spokesperson told the Wall Street Journal that the move is in response to the prevalence and widespread availability of CBD products.
Google says it will update its Dangerous Products & Services and Healthcare & Medicines policies on January 20.
The company will also remove CBD from the Unapproved Pharmaceuticals and Supplements list.
The updated policies will allow for the promotion of FDA-approved CBD-infused products and topical hemp-derived products with 0.03 percent THC or less.
Google says it will not allow ads for other CBD products, like supplements, food additives, and inhalants.
The company says the policy updates do not apply to digital billboards on the YouTube Masthead platform.
Google will allow the ads to run in California, Colorado, and Puerto Rico.
In the U.S., the company will only allow LegitScript-certified topical CBD product ads to run.
Companies will need to submit samples of their products to LegitScript and pay the required fees to obtain certification.
LegitScript does not certify FDA-approved pharmaceuticals containing CBD.
Advertisers with LegitScript certification or FDA approval must also obtain Google certification before running ads.
Advertisers can request certification on January 20 when it publishes the form.